Sequenom Appoints Paul W. Hawran to Board of Directors
Sequenom, a biomedical company, has appointed Paul W. Hawran to its board of directors, where he will chair the audit committee. Hawran brings a wealth of experience in financial leadership, having joined Neurocrine Biosciences as vice president and chief financial officer in 1993 and later serving as executive vice president and chief financial officer since 2001. He has also held various financial positions at SmithKline Beecham Corporation, Warner Communications, and Time Warner, Inc. Hawran's appointment expands the board's membership to eight, with Dr. Hixson continuing to serve as chairman of the board of directors and member of the compensation and nominating and corporate governance committees.
Key Takeaways:
- Paul W. Hawran was appointed to Sequenom's board of directors, bringing extensive financial leadership experience.
- Hawran has held various executive positions at Neurocrine Biosciences, SmithKline Beecham Corporation, and Time Warner, Inc.
- He received an MS in taxation from Seton Hall University and a BS in finance from St. John's University.
- Hawran is a member of several professional organizations, including the American Institute of Certified Public Accountants and the Financial Executives Institute.
- His appointment expands the board's membership to eight, with Dr. Hixson continuing to serve as chairman.
- Hawran will chair the audit committee.
Statistics:
- 1993: Paul W. Hawran joined Neurocrine Biosciences as vice president and chief financial officer.
- 2001: Hawran was promoted to executive vice president and chief financial officer at Neurocrine Biosciences.
- 8: Number of members on Sequenom's board of directors after Hawran's appointment.
- 2: Number of board committees where Dr. Hixson continued to serve, in addition to chairman of the board of directors.
Sources:
- Health & Medicine Week editors
- NewsRx.com (2006)